Saturday 17 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

156.19 1.18 −0.75%

Follow GILD

Alert me

Market cap: $195.1B
P/E: 0.0×
Fwd P/E: −46.2×
Dividend yield: 2.08%
F-score: 8/9
Altman Z: 4.03
Beneish M: −2.45
Dividend safety: 77/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 85.75

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	6	3	5	4	3	3	2	3	3	5	3	1

Insider Ownership 0.24%

Capital & Financial Ratios $m

Market Cap 195,130.00

Revenue 30,457.00

Net Income (3,240.00)

Free Cash Flow 12,943.00

Net Debt 23,067.00

Current Ratio 1.27

Debt/Equity 2.23

P/E ratio 0.00

Fwd P/E (46.20)

P/S ratio 6.37

P/B ratio 16.53

Past 5Y EPS Growth 132.41%

This Y EPS Growth (105.05%)

Next Y EPS Growth 2,526.43%

Next Y revenue growth 37.32%

Next 5Y EPS Growth 9.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 99.63%

10-year low 10-year high

P/B against its own 10 years 99.96%

10-year low 10-year high

EV/Sales against its own 10 years 99.85%

10-year low 10-year high

EV/FCF against its own 10 years 90.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 3.25

Annual Dividend Yield 2.08%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	4.33	0.82 0.82 0.82
2025	4.49	0.79 0.79 0.79 0.79
2024	3.08	0.77 0.77 0.77 0.77
2023	3.00	0.75 0.75 0.75 0.75
2022	2.92	0.73 0.73 0.73 0.73
2021	2.84	0.71 0.71 0.71 0.71
2020	2.72	0.68 0.68 0.68 0.68
2019	2.52	0.63 0.63 0.63 0.63
2018	2.28	0.57 0.57 0.57 0.57
2017	2.08	0.52 0.52 0.52 0.52
2016	1.84	0.43 0.47 0.47 0.47

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7,264	9,991	7,632	3,179
Receivables	4,660	4,420	4,913	5,055
Inventory	1,787	1,710	1,774	1,953
Other	—	—	—	—
	16,085	19,173	18,342	13,945

	2023	2024	2025	Q'26
Payables	550	833	715	674
ST’ Debt	1,798	1,815	2,807	2,414
Other	5,130	5,464	3,953	3,699
	11,280	12,004	11,813	11,020

Compound Annual Growth %

	10y	5y	3y
Sales	(1.03%)	3.58%	2.57%
Cash Flow	(7.24%)	4.17%	3.37%
Earnings	(7.27%)	133.35%	22.83%
Book Value	1.70%	4.42%	2.17%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6,960	7,803	—	—	—
’25	6,667	7,082	7,769	7,925	29,443
’24	6,686	6,954	7,545	7,569	28,754
’23	6,352	6,599	7,051	7,114	27,116
’22	6,590	6,260	7,042	7,389	27,281
’21	6,423	6,217	7,421	7,244	27,305
’20	5,548	5,143	6,577	7,421	24,689

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,544	3,573	—	—	—
’25	1,757	827	4,108	3,327	10,019
’24	2,219	1,325	4,309	2,975	10,828
’23	1,744	2,338	1,755	2,169	8,006
’22	1,840	1,802	2,863	2,567	9,072
’21	2,610	2,316	3,253	3,205	11,384
’20	1,436	2,566	2,250	1,916	8,168

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,427	3,433	—	—	—
’25	1,653	720	3,961	3,122	9,456
’24	2,114	1,195	4,168	2,828	10,305
’23	1,635	2,199	1,633	1,954	7,421
’22	1,593	1,659	2,706	2,386	8,344
’21	2,445	2,197	3,114	3,049	10,805
’20	1,265	2,423	2,095	1,735	7,518

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.61	(8.45)	—	—	—
’25	1.04	1.56	2.43	1.74	6.78
’24	(3.34)	1.29	1.00	1.42	0.38
’23	0.80	0.83	1.73	1.14	4.50
’22	0.02	0.91	1.42	1.30	3.64
’21	1.37	1.21	2.05	0.30	4.93
’20	1.22	(2.66)	0.29	1.23	0.10

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	70.83	63.76	60.32	60.89	56.56	57.93	57.17	72.87	62.07	88.57	Analyst estimates 2026–2028 Powerpack
	High	103.10	86.27	89.54	70.50	85.97	74.12	89.74	88.29	98.90	128.70
People
People	Employees	9,000	10,000	11,000	11,800	13,600	14,400	17,000	18,000	17,600	17,000
	Revenue/emp, $m	3.38	2.61	2.01	1.90	1.82	1.90	1.60	1.51	1.63	1.73
Income, $m
Income, $m	Revenue	30,390	26,107	22,127	22,449	24,689	27,305	27,281	27,116	28,754	29,443
	Gross margin, %	85.98	83.26	78.07	79.18	81.48	75.82	79.26	76.04	78.26	78.83
	EBT	17,097	13,529	7,799	5,160	1,669	8,278	5,814	6,859	690	9,796
	EBT margin, %	56.26	51.82	35.25	22.99	6.76	30.32	21.31	25.30	2.40	33.27
	Net income	13,488	4,644	5,460	5,364	89	6,201	4,566	5,613	480	8,510
	Depreciation	1,158	1,286	1,429	1,404	1,480	2,050	2,103	2,693	2,767	2,760
Per share, $
Per share, $	Revenue	22.70	19.97	17.05	17.68	19.64	21.74	21.74	21.73	23.06	23.67
	Earnings	10.08	3.54	4.20	4.24	0.10	4.96	3.66	4.54	0.38	6.84
	Cash flow	12.73	9.10	6.47	7.20	6.50	9.06	7.23	6.42	8.68	8.05
	Capex	(0.56)	(0.45)	(0.71)	(0.65)	(0.52)	(0.46)	(0.58)	(0.47)	(0.42)	(0.45)
	Free cash flow	12.17	8.65	5.76	6.55	5.98	8.60	6.65	5.95	8.26	7.60
	Book value	14.46	15.69	16.59	17.83	14.50	16.77	16.90	18.23	15.43	18.18
	Shares, m	1,339	1,307	1,298	1,270	1,257	1,256	1,255	1,248	1,247	1,244
Valuation, ×
Valuation, ×	P/E	7.36	20.93	14.89	15.33	582.60	14.67	23.27	18.29	243.08	17.92
	P/S	3.27	3.71	3.67	3.68	2.97	3.34	3.93	3.83	4.01	5.19
	P/B	5.13	4.72	3.77	3.64	4.02	4.33	5.05	4.57	5.98	6.75
	EV/Sales	3.78	4.04	3.59	3.73	3.99	4.11	4.66	4.53	4.59	5.77
	EV/FCF	7.04	9.32	10.63	10.07	13.09	10.40	15.24	16.56	12.80	17.98
Cash, $m
Cash, $m	Operating cash flow	17,047	11,898	8,400	9,144	8,168	11,384	9,072	8,006	10,828	10,019
	Capex	(748)	(590)	(924)	(825)	(650)	(579)	(728)	(585)	(523)	(563)
	Free cash flow	16,299	11,308	7,476	8,319	7,518	10,805	8,344	7,421	10,305	9,456
Balance, $m
Balance, $m	Working capital	10,370	20,188	25,231	20,537	4,599	3,162	3,206	4,805	7,169	6,529
	Total debt	26,643	34,100	28,362	25,602	32,616	27,671	26,409	26,267	26,711	24,936
	Net debt	14,748	8,590	(1,727)	1,250	25,208	21,151	20,024	19,003	16,720	17,304
	Shareholders’ equity	19,363	20,501	21,534	22,650	18,221	21,064	21,209	22,749	19,246	22,618
Returns, %
Returns, %	ROA	24.84	7.27	8.14	8.60	0.19	9.13	7.00	9.04	0.79	14.42
	ROIC	32.31	30.34	25.87	11.21	5.86	14.68	11.11	11.38	2.89	15.69
	ROE	70.18	23.22	25.95	24.38	0.60	31.69	21.73	25.77	2.29	40.66

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MRK Merck & Co., Inc.	$358.2B	117×	53.9×	+5.07% (above 0%: growing)	n/m	+77.03% (above 0%: growing)	73.54%	(2.61%)	Compare
NVS Novartis AG	$275.3B	22.6×	20.6×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$258.5B	24.5×	23.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%	Compare
AMGN Amgen Inc.	$234.7B	26.7×	22.7×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$195.1B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)
PFE Pfizer Inc.	$167.8B	38.9×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
NVO Novo Nordisk A/S	$131.2B	9.5×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$123.7B	13.2×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%	Compare
GSK GSK PLC Sponsored ADR	$98.2B	15.4×	12.4×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%	Compare
Median of peers	$201.2B	23.6×	20.6×	+5.41%	−7.74%	+63.20%	73.30%	26.03%

All 21 Drug Manufacturers General stocks →

Gilead Sciences, Inc. (GILD) key facts

Strength: Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
Gilead Sciences, Inc. (GILD) is a Drug Manufacturers General company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GILD traded at $156.19, a market capitalization of $195.1 billion.
Gilead Sciences, Inc. pays an annual dividend of $3.25 per share, a yield of 2.08%.
Return on equity was 40.7% and debt-to-equity 2.23.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 4.03 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Financial Analysis (summary)

Updated 29 September 2026

Gilead Sciences reported revenue of $29.4 billion in FY2025, with net income of $8.5 billion and free cash flow of $9.5 billion in FY2025. Revenue growth was 2.40% in FY2025 against FY2024, while annual operating margin reached 34.0% in FY2025.

In Q2 FY2026, revenue was $7.8 billion, but operating income was −$10.4 billion and net income was −$10.5 billion. Free cash flow was $3.4 billion in Q2 FY2026, while net debt was $23.1 billion in Q2 FY2026. Management attributes the quarterly loss primarily to higher operating expenses.

Read the full analysis →